ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,283Medicare Part D Prescriptions Filled, Including Refills

Rank: 171 out of 973

$442K Total Retail Price of All Prescriptions

Rank: 192 out of 973

488 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
33% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Kansas
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 488 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

14% of this provider’s 488 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 7,861 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Kansas
POTASSIUM CHLORIDE 414 398 1 9
LEVOTHYROXINE SODIUM 389 330 2 2
HYDROCODONE-ACETAMINOPHEN 297 203 S3 3 4
FUROSEMIDE 261 251 4 6
SYNTHROID 239 218 5 50
HYDROCHLOROTHIAZIDE 237 229 6 11
SIMVASTATIN 232 226 7 1
OMEPRAZOLE 222 171 8 5
WARFARIN SODIUM 215 185 9 10
LISINOPRIL 209 184 10 3
POLYETHYLENE GLYCOL 3350 206 206 11 36
AMLODIPINE BESYLATE 165 161 12 7
METOPROLOL SUCCINATE 161 127 13 17
METOPROLOL TARTRATE 159 118 14 13
METFORMIN HCL 141 116 15 8
GABAPENTIN 139 119 16 12
ATORVASTATIN CALCIUM 117 113 17 15
LOSARTAN POTASSIUM 95 82 18 19
SERTRALINE HCL 94 74 19 21
TRIAMTERENE-HCTZ 92 76 20 51
FENTANYL 85 82 S2 21 53
TRAMADOL HCL 84 74 22 18
ATENOLOL 82 64 23 16
ALENDRONATE SODIUM 76 70 24 24
DILTIAZEM 24HR CD 74 72 25 104
FLUOXETINE HCL 72 60 26 56
AMITRIPTYLINE HCL 71 59 R 27 52
LANTUS SOLOSTAR 69 66 28 99
QUETIAPINE FUMARATE 67 62 29 70
AZITHROMYCIN 67 55 29 47
SULFAMETHOXAZOLE-TRIMETHOPRIM 63 55 31 76
TAMSULOSIN HCL 63 63 31 28
ENALAPRIL MALEATE 62 60 33 55
ZOLPIDEM TARTRATE 60 57 34 20
ISOSORBIDE MONONITRATE ER 59 59 35 85
TRAZODONE HCL 58 35 36 48
OXYCODONE-ACETAMINOPHEN 57 37 S2 37 89
PREDNISONE 57 44 37 33
DIGOXIN 56 56 39 32
CIPROFLOXACIN HCL 55 49 40 57
DONEPEZIL HCL 54 54 41 26
PEN NEEDLE 53 51 42 171
CITALOPRAM HBR 53 42 42 14
NOVOLOG FLEXPEN 53 51 42 168
DIOVAN 50 50 45 63
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.